Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Novartis
Dow
Citi
Cipla
Deloitte
Federal Trade Commission
Cantor Fitzgerald
Boehringer Ingelheim

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,247,402

« Back to Dashboard

Which drugs does patent 8,247,402 protect, and when does it expire?

Patent 8,247,402 protects DORIBAX and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.
Summary for Patent: 8,247,402
Title:Crystal form of pyrrolidylthiocarbapenem derivative
Abstract: Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfa- moylaminomethyl)p yrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) and a crystal of said compound having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are provided.
Inventor(s): Saitoh; Izumi (Hyogo, JP), Takahira; Masayuki (Hyogo, JP), Kawakita; Toshio (Hyogo, JP), Yoshioka; Yasuyuki (Hyogo, JP)
Assignee: Shiongi & Co., Ltd. (Osaka, JP)
Application Number:12/012,932
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Process;

Drugs Protected by US Patent 8,247,402

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,247,402

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-99868Mar 31, 2000

Non-Orange Book US Patents Family Members for Patent 8,247,402

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,247,402

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2404703 ➤ Subscribe
Australia 4469201 ➤ Subscribe
China 1432016 ➤ Subscribe
China 1192030 ➤ Subscribe
Germany 60113243 ➤ Subscribe
Denmark 1270575 ➤ Subscribe
European Patent Office 1270575 ➤ Subscribe 333 Finland ➤ Subscribe
Taiwan I293631 ➤ Subscribe
Spain 2252205 ➤ Subscribe
Japan 3375084 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Mallinckrodt
Julphar
Farmers Insurance
Novartis
Queensland Health
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot